Abiomed, Inc receives Canadian regulatory approval for Impella technologies
Medical products and services provider Abiomed, Inc. (Nasdaq: ABMD) said Wednesday morning that it received Canadian regulatory approval for its Impella circulatory support technologies.
The company said its product was approved for use in Canada by Health Canada’s Therapeutic Products Programme.
The Impella devices are said to be a key treatment option for clinicians in Canada’s catheterization laboratory and surgical suites. Abiomed’s Impella 2.5 is a ventricular assist catheter, which is inserted percutaneously in the catheterization laboratory via the femoral artery into the left ventricle.
